Highlights d The molecular profile of RMC distinguishes it from other renal malignancies d RMC harbors a high number of focal chromosomal alterations d RMC has a distinct immune profile characterized by upregulation of cGAS-STING d DNA replication stress is a hallmark of RMC that can be therapeutically targeted

Melanoma cell phenotype switching between differentiated melanocytic and undifferentiated mesenchymal‐like states drives metastasis and drug resistance. CDK7 is the serine/threonine kinase of the basal transcription factor TFIIH. We show that dedifferentiation of melanocytic‐type melanoma cells into mesenchymal‐like cells and acquisition of tolerance to targeted therapies is achieved through chronic inhibition of CDK7. In addition to emergence of a mesenchymal‐type signature, we identify a GATA6‐dependent gene expression program comprising genes such as AMIGO2 or ABCG2 involved in melanoma survival or targeted drug tolerance, respectively. Mechanistically, we show that CDK7 drives expression of the melanocyte lineage transcription factor MITF that in turn binds to an intronic region of GATA6 to repress its expression in melanocytic‐type cells. We show that GATA6 expression is activated in MITF‐low melanoma cells of patient‐derived xenografts. Taken together, our data show how the poorly characterized repressive function of MITF in melanoma participates in a molecular cascade regulating activation of a transcriptional program involved in survival and drug resistance in melanoma.